Drug safety: COVID-19 complicates already challenged FDA foreign inspection program : testimony before the Committee on Finance, U.S. Senate /
Saved in:
Main Author: | Denigan-Macauley, Mary (Author) |
---|---|
Corporate Authors: | United States. Government Accountability Office (Author), United States. Congress. Senate. Committee on Finance (sponsoring body.) |
Format: | Government Document Electronic eBook |
Language: | English |
Published: |
[Washington, District of Columbia] :
United States Government Accountability Office,
[2020]
|
Series: | Testimony ;
GAO-2-626T. COVID-19: pandemics past and present. |
Subjects: | |
Online Access: | CONNECT |
Similar Items
-
Drug safety: COVID-19 complicates already challenged FDA foreign inspection program : testimony before the Committee on Finance, U.S. Senate /
by: Denigan-Macauley, Mary
Published: (2020) -
Drug safety, FDA has improved its foreign drug inspection program, but needs to assess the effectiveness and staffing of its foreign offices : report to the Committee on Energy and Commerce.
Published: (2016) -
Drug safety: FDA's future inspection plans need to address issues presented by COVID-19 backlog : testimony before the Subcommittee on Agriculture, Rural Development, Food and Drug Administration, and Related Agencies, Committee on Appropriations, House of Representatives /
by: Denigan-Macauley, Mary
Published: (2021) -
Drug safety: FDA's future inspection plans need to address issues presented by COVID-19 backlog : testimony before the Subcommittee on Agriculture, Rural Development, Food and Drug Administration, and Related Agencies, Committee on Appropriations, House of Representatives /
by: Denigan-Macauley, Mary
Published: (2021) -
Science and mission at risk : FDA's self-assessment : hearing before the Subcommittee on Oversight and Investigations of the Committee on Energy and Commerce, House of Representatives, One Hundred Tenth Congress, second session, January 29, 2008.
Published: (2008)